跳至主要内容
临床试验/NCT06176430
NCT06176430尚未招募4 期

Comparison of Twice Weekly Versus Daily Iron Therapy in Treating Anemia in Children With Cerebral Palsy

Shaheed Zulfiqar Ali Bhutto Medical University0 个研究点目标入组 160 人开始时间: 2024年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
尚未招募
入组人数
160
主要终点
Change in Hemoglobin levels from baseline

研究概览

简要总结

a randomized clinical trial to compare the effect of twice weekly versus daily iron therapy in treating anemia in children with cerebral palsy, to be conducted at Department of pediatric medicine children's hospital PIMS islamabad.

详细描述

a total of 160 children of either gender with age between 6 and 60 months diagnosed with cerebral palsy and concomitant iron deficiency anemia will be enrolled, they will be allocated two groups by lottery method. one group will be given ferrous sulphate 3mg/kg daily in the form of syrup and other group will be given ferrous sulphate 3mg/kg twice weekly in the form of syrup for a period of 4 weeks. the primary outcome will be measured as rise in hemoglobin levels more than or equal to 1g/dl at 4 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

laboratory personnel only will be blind

入排标准

年龄范围
6 Months 至 60 Months(Child)
性别
All
接受健康志愿者

入选标准

  • All the children with cerebral palsy who are diagnosed cases of iron deficiency anaemia
  • Age 06 months to 5 years
  • Both genders

排除标准

  • >5 years of age
  • Children with severe anaemia requiring transfusion (Hb<5 g/L)
  • Children with history of taking oral/IV iron supplements or repeated blood transfusions during last one month
  • Children with concomitant diarrheal disease
  • Where parents are not willing to participate in the study

研究组 & 干预措施

Daily Group

Active Comparator

one group will receive ferrous sulphate 3mg/kg in the form of syrup daily

干预措施: Ferrous Sulfate Oral Product (Drug)

Twice Weekly Group

Sham Comparator

other group will receive ferrous sulphate 3mg/kg in the form of syrup twice weekly.

干预措施: Ferrous Sulfate Oral Product (Drug)

结局指标

主要结局

Change in Hemoglobin levels from baseline

时间窗: 4 weeks

rise in Hb at the end of 4 weeks as more than equal to 1g/dl

次要结局

  • Mean change in MCV (Mean Corpuscular Volume)(4 weeks)
  • Mean change in mean corpuscular hemoglobin concentration (MCHC)(4 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr Yusra Kafait

Pediatrics Resident

Shaheed Zulfiqar Ali Bhutto Medical University

相似试验